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Abstract 
 
Aim- To discuss different classes of antiresorptive agents and their modes of action. To review the 
proposed mechanisms in the pathophysiology of osteonecrosis development. To analyse the 
prevention and the management of medication related osteonecrosis of the jaw. 
 
Materials and methods- Three databases were searched for relevant articles: PubMed, Ovid and 
Dentistry and Oral Sciences Source. Current literature consists mainly of case series, case reports 
and expert body opinions. 
 
Discussion- The repertoire of antiresorptive medication keeps expanding as novel drugs are being 
introduced. The exact pathway that leads to the development of osteonecrosis remains to be 
elucidated but different mechanisms have been put forward. An attempt at staging has been made 
and treatment guidelines have been drawn but opinions remain divided. New treatments are being 
trialled, however, evidence is lacking.  
 
Clinical relevance 
Medication related osteonecrosis of the jaw represents a dilemma for the practitioner. It is important 
for operators to understand the mechanism behind the lesion, prevention and recognition of the 
lesion and be up to date with the appropriate treatment. As patients at risk of necrosis are on the 
rise, dentists will be at the forefront of its’ prevention. 
 
 
 
 
 
 
 
 
 
 
 
 
Definition 
Osteonecrosis is the death of bone cells due to lack of blood supply (1). The nomenclature 
‘medication related osteonecrosis of the jaw’ (MRONJ) was adopted in 2014 and preferred to the 
former term ‘bisphosphonate related osteonecrosis of the jaw’ (BRONJ). This change was to 
accommodate the new classes of drugs involved in osteonecrosis. These drugs include new 
angiogenic and antiresorptive agents (2). Table 1 includes a list of antiresorptive medications. 
A diagnosis of MRONJ can be made if patients are on current or past treatment with angiogenic or 
antiresorptive medications, have no history of head and neck malignancy or radiotherapy to the area 
and have exposed bone for more than eight weeks (2,3). 
 
Incidence 
There is difficulty in obtaining exact incidence data for MRONJ because of underreporting of cases 
together with discrepancies in case recognition. The available data is extrapolated from retrospective 
studies with small sample sizes. The incidence in cancer patients on intravenous therapy is between 
1.2 to 19%. For patients being treated by oral medication for osteoporosis, the risk of MRONJ is 1 in 
1262 per year. In the UK, there are on average 620 new cases a year (4-6).   
 
 
 
 
 
 
 
 
 
 
Table 1: Antiresorptive medications and indications (7) 
 
 
 
 
 
 
 
Antiresorptive medication 
 
Bisphosphonates 
The majority of MRONJ cases are from bisphosphonates. Bisphosphonates are a group of antire-
sorptive medication effective on bone. Non-nitrogen containing bisphosphonates like etidronate have 
been approved by the Food and Drug Administration (FDA) since 1977 and have not been involved 
in ONJ. Nitrogen containing bisphosphonates (N-bisphosphonates) like pamidronate have been cir-
culated since 1991 and are reported to be up to 700 times more potent than etidronate. Pamidro-
nate, because of its’ higher potency, does not get metabolised. It is the accumulation of the drug 
over time that predisposes patients to osteonecrosis. Bisphosphonates are thought to work by inhibi-
tion of osteoclastic activity (8,9). Other proposed mechanisms include alteration of bone turnover 
and inhibition of angiogenesis (2,3,8). The mode of action is discussed in further detail later in the 
text. 
 
Receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor 
Denusomab is a fully human monoclonal antibody and a potent antiresorptive agent. RANKL is a 
member of the tumour necrosis factor (TNF) superfamily and is the main mediator of osteoclastic 
bone resorption (7). RANKL binds to its receptor RANK to produce and activate osteoclasts and 
suppress their apoptosis. Denusomab inhibits binding of RANKL to its receptor, reducing number of 
functioning osteoclasts, achieving near total suppression of osteoclastogenesis (10). Denusomab 
reduces the risk of bone fracture by increasing bone density (7). Denusomab affects production of 
osteoclasts whereas bisphosphonates affect their resorptive power. However, their efficacies as anti-
resoptive agents are the same (10). 
 
Anabolic agents 
Recombinant human parathyroid hormone, teriparatide, encourages bone formation through osteo-
blast activation. It is believed that teriparatide may emerge as the medication of choice for osteopo-
rosis. Early studies have shown resolution of osteonecrosis with teriparatide treatment (7). 
 Antiangiogenic agents  
Vascular endothelial growth factor (VEGF) inhibitor. 
Bevacizumab is a recombinant human monoclonal antibody that inhibits angiogenesis by inhibiting 
VEGF. It is used in combination with standard chemotherapy for treatment of metastatic cancer (11). 
 
Tyrosine kinase receptor (TKR) inhibitor  
TKR inhibitors like sunitinib are used for treatment of renal carcinoma and gastrointestinal tumours. 
Sunitinib inhibits cellular signalling by targeting multiple TKRs. Among these multiple TKRs, are re-
ceptors responsible for tumour cell proliferation and VEGF responsible for angiogenesis (11). 
 
Pathophysiology 
Although MRONJ was recognised more than 10 years ago, its’ pathophysiology is not fully under-
stood. With the emergence of ONJ caused by new medications like denusomab, researchers are 
focusing on mechanisms common to both bisphosphonates and denusomab. The common hypothe-
ses are inhibition of osteoclastic activity and remodelling, bone turnover, infection and inflammation, 
inhibition of angiogenesis, genetic predisposition, immune dysfunction and idiopathic (2,3,8). 
 
Inhibition of osteoclastic activity and remodelling 
N-bisphosphonates pass into the cell and inhibit prenylation of guanosine triphosphate proteinase; 
which are required for survival of working osteoclasts (12). Non-N-bisphosphonates also enter the 
cell by endocytosis. The agent then accumulates in the cell up to a toxic level (13).  
Osteoblasts differentiate into osteocytes. Secretion of hydroxyapatite crystals in the collagen matrix 
of mineralised bone then surrounds the osteocytes.  
Bone formation follows the release of cytokines such as bone morphogenic protein (BMP) and insu-
lin like growth factors 1 and 2. The cytokines induce mesenchymal cells and osteoprogenitors to dif-
ferentiate into osteoblasts. Osteoclasis causes the release of the aforementioned cytokines. As the 
bisphosphonates affect osteoclasts, normal osteoclasis is affected, which in turn affects the remodel-
ling. When the surrounded osteocytes exceed their life span of 150 days, they cannot maintain the 
structural integrity of the matrix and microfractures develop (9). 
 
It is postulated that, like bisphosphonates, denusomab also leads to an end effect of decreased os-
teoclastic activity and remodelling by inhibiting osteoclasts and increasing apoptosis. Bone remodel-
ling occurs via the same mechanism throughout the whole skeleton. However, osteonecrosis has 
been observed primarily in the alveolar process of the bi-maxilla. Animal studies have shown re-
duced bone remodelling of the jaws. This supports the idea that necrosis occurs preferentially in the 
jaws because of increased bone turnover at the site. Other antiresorptive medications like 
denusomab have been found to cause similar rates of osteonecrosis as bisphosphonates. This fact 
further strengthens the pivotal part of decreased bone remodelling in ONJ (2). Bisphosphonates can 
be taken up by any endocytic cells; especially osteoclasts. Osteoclasts are preferred because they 
reside in Howship’s lacunae and release carbonic anhydrase to dissolute bone. The acid easily re-
leases bisphosphonates from the matrix. High concentrations of the drug in Howship’s lacunae and 
surroundings are believed to affect proximate osteoblasts, but evidence is lacking. 
Haematopoietic cells and adipocytes of the bone marrow can also take up bisphosphonates. Accu-
mulation of the drug can affect function which is demonstrated by the fevers, myalgias and arthralgi-
as experienced by users after administration of high dose intravenous bisphosphonates. In vitro 
studies have explained the role of osteoblasts, fibroblasts and oral keratinocytes in necrosis. Their 
cell life and multiplication are negatively affected by bisphosphonates in a dose dependent relation-
ship. This new information provides understanding of the way other cells are affected by bisphos-
phonates but it is not possible to measure the individual drug concentrations in patients’ tissues. 
While the effect of bisphosphonates on bone marrow cells are acknowledged, the occurrence of ne-
crosis in denusomab patients suggest these effects are not critical in causing osteonecrosis. These 
observations reiterate the major role of decreased bone remodelling in causing ONJ (13,14). 
 
Bone turnover 
It has been proposed that low bone turnover; the main feature of successful treatment with antire-
sorptive drugs, plays a role in osteonecrosis. The increased risk of osteonecrosis with higher doses 
of antiresorptive drugs backs up this theory (3,10). However, considerably reduced osteoclasis 
caused by the drugs would result in osteopetrosis and not osteonecrosis. Osteonecrosis is not asso-
ciated with other conditions of low bone turnover like hypoparathyroidism. High osteoclast numbers 
have been detected in bone samples of lesion sites, whereby bone lysis is presented radiographical-
ly. Canine studies demonstrated areas of spontaneous bone necrosis with dead osteocytes in sub-
jects treated with high dose antiresorptives (3).  Several researchers found no suppression in bone 
turnover in patients with osteonecrosis (3,15,16). Nuclear bone scanning of patients with metastatic 
breast carcinoma treated with antiresorptives failed to demonstrate high bone turnover in the maxilla 
and mandible. Developing microfractures following low bone turnover may precipitate osteonecrosis, 
however supporting evidence is lacking (10) 
 
Inflammation and infection  
The first reported cases of osteonecrosis were following dental extractions; which pointed to surgical 
trauma as the cause. Dental extractions are usually due to pathology. Several studies have implicat-
ed inflammation and infection in the development of osteonecrosis. It is however indeterminate as to 
whether necrosis comes before or after infection. It has been demonstrated that antiresorptive medi-
cation coupled with inflammation or infection alone are enough to prompt osteonecrosis. Infection 
could explain local osteolysis normally found in osteonecrotic sites despite patients being on high 
dose antiresorptive medication (10). Certain bacterial by-products can increase local cytokine pro-
duction and other microbes can have direct effects on B cells and receptor activator nuclear factor 
ƙB ligand (RANKL), culminating in increased osteoclastic action (17).  
Histology of excised necrotic jaw specimens identified bacteria, viruses and fungi; co-existing in bio-
films (2). Actinomyces may be an important factor in high grade osteonecrosis and is isolated in 
most osteonecrosis specimens (18).  Presence of actinomyces at osteonecrotic sites may be oppor-
tunistic because oral actinomyces are common but actinomycosis is uncommon (19). The polysac-
charide matrix that makes up the biofilm often conceals presence of pathogens to microscopy (10). 
Polymorphonuclear leukocytes have also been found in biofilms. This cluster of microorganisms may 
directly contribute to ONJ. Khan et al. proposed that bisphosphonates hinder cell division and viabil-
ity of oral epithelium. This hindrance together with dental infection or trauma is thought to further 
damage the structure of oral mucosa, leading to necrosis (3). However, an in-vitro study did not 
demonstrate any effect on cell migration by alendronate or zoledronate. They concluded that sup-
pression of oral keratinocytes is not a factor in osteonecrosis. (20).  
The risk of developing ONJ from inflammation, infection and following surgical procedures is in-
creased in patients on intravenous bisphosphonates (16). Via a strict preventative dental pro-
gramme, Bramati et al. reduced the occurrence of ONJ in oncology patients. This highlights the role 
of bacterial infection in osteonecrosis (21). In animals, researchers have induced osteonecrosis from 
bacterial infection alone (2). They have also prevented the onset of osteonecrosis with antibiotics 
and mucoperiosteal flap coverage following exodontia (10). The acidic environment created by infec-
tion releases bisphosphonates from their matrix. High concentrations of bisphosphonates affect os-
teoblasts and facilitate osteonecrosis development.  
Oral infection attracts macrophages to the area (22). Bisphosphonates, following their administration, 
are in circulation shortly before they become bound to bone. During this period of circulation, macro-
phages can be ahead of osteoclasts to phagocytose bisphosphonates (23). With repeated intake of 
bisphosphonates, active bone sites decrease, which allows non-bone cells to take up the drug. Mac-
rophages in contact with bisphosphonates lose their ability to defend against micro-organism inva-
sion (15). 
 
Inhibition of angiogenesis 
Angiogenesis is the process of forming new blood vessels. Angiogenic growth factors like VEGF ac-
tivate receptors on endothelial cells which proliferate, forming new vessels. Angiogenesis is funda-
mental in cancer metastasis through tumour invasion of vessels. Osteonecrosis was historically 
termed avascular necrosis of the jaw and angiogenesis was the prime hypothesis in osteonecrosis 
histopathology. N-bisphosphonates are known to inhibit angiogenesis. Laboratory experiments have 
reliably shown downregulation of angiogenesis with zoledronate (2). In oncology patients on intrave-
nous zoledronate, VEGF and platelet derived growth factors were reduced (24). Osteonecrosis of 
other bones is occurring in patients with new antiangiogenic drugs like TKR inhibitors and monoclo-
nal antibody targeting VEGF (2,3). Denusomab related cases of osteonecrosis have been reported, 
however, denusomab is not known to inhibit angiogenesis. Moreover, biopsy sample analysis of os-
teonecrosis lesions found vasculature to be patent in most cases. Osteonecrosis appears in the 
maxilla as well as the mandible (10). However, the mandible can be up to 9 times more affected than 
the maxilla (25). While the maxilla is highly vascularised, the dense bone of the mandible coupled 
with its’ comparatively lower vascularity could explain the difference in occurrence rate (25). Vascu-
lar volume in animals was unchanged after administration of N-bisphosphonates (3). Due to the lack 
of hard evidence linking angiogenesis to osteonecrosis, the term ‘avascular necrosis’ was dropped.  
 
Immunosuppression 
Immunosuppression has been proposed as a risk for osteonecrosis. Chemotherapy drugs cause 
immunosuppression by either suppressing the bone marrow function or from the high dose of gluco-
corticoid (26). Sonis et al. could only consistently induce osteonecrosis in rats when zolendronic acid 
was combined with dexamethasone (27). Dexamethasone causes delayed wound healing and alter-
ation in microflora, predisposing the subject to infection (10). Further investigation on bisphospho-
nates and dexamethasone showed that T regulatory cells 17, which participate to control and pre-
vent autoimmune disease, were activated. At the same time, regulatory T cells which modulate the 
immune system were suppressed. Mesenchymal stem cells reversed the osteonecrosis, thereby 
strengthening the theory of immune dysfunction as a cause for osteonecrosis (28). Bisphosphonates 
act as gamma delta T cells receptor agonists and increase production of proinflammatory cytokines 
followed by diminution of T cells, impairing immune function (3). 
Vitamin D influences the immune system and is vital for calcium absorption. Animals with vitamin D 
deficiency treated with bisphosphonates, developed osteonecrosis following exodontia. Thus, immu-
nodeficiency could predispose oncology patients to osteonecrosis (26). 
 
Genetic predisposition 
In patients with similar comorbidities receiving same drug treatment, the development of osteonecro-
sis is not standardised. Genetics may play a role in its’ development. The suggestions are alterations 
in farnesyl pyrophosphate synthase or cytochrome P450-CYP2C8 genes. Genetic studies are ongo-
ing in this area (3). 
 
Cytotoxicity  
Bisphosphonate toxicity can be to hard or soft tissues. Toxicity could be from long term use, high 
doses and accumulation of bisphosphonates in bone tissue. Bisphosphonates act locally and not 
systemically, mainly affecting the jaws (4). Necrotic areas with dead osteocytes were found in ani-
mals treated with bisphosphonates. The toxic effects of the bisphosphonates caused the cell death 
but suppression of bone remodelling could also be a plausible explanation for the necrotic areas. N-
bisphosphonates inhibit cell division by inhibition of farnesyl diphosphate synthase found in oste-
oclats (10).  
Although bisphosphonates bind to bone, soft tissue toxicity has been described. Several cell types 
including cervical and oral epithelial cells have exhibited decreased cell multiplication after contact 
with bisphosphonates in vitro. In vivo, patients have experienced gastrointestinal symptoms after 
administration of bisphosphonates. As bisphosphonates are excreted via the kidneys a few hours 
after administration, the window for uptake by non-bone cells is small (2). Experiments showed the 
doses of bisphosphonates required to halt cell proliferation was similar to those found in patients re-
ceiving intravenous zoledronate. In previously exposed bone, dental surgery may result in bisphos-
phonate release into the area. High drug concentrations can prevent replication of oral epithelial 
cells, lengthening mucosal healing (10).  Denusomab is not known to cause cytotoxicity. 
 
Local factors 
Local trauma from surgical procedures like exodontia, endodontic or periodontal surgery is a trigger 
factor MRONJ development. A study found that 60% of osteonecrosis cases were caused by dento-
alveolar insult/trauma. Spontaneous osteonecrosis in absence of antiresorptives has been reported 
after endotracheal intubation. This emphasises the role played by alveolar bone trauma in the devel-
opment of osteonecrosis (4). 
 
 
Figure1. Proposed mechanisms for the development of ONJ (10) 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Proposed mechanisms for ONJ development (4) 
 
 
Management 
Staging 
A staging system for osteonecrosis allows data collection on an international level, directing 
treatment strategies and assessing prognosis of patients on antiresorptive medication. The system 
includes the stages ‘0’ to ‘3’. The International Task Force on Osteonecrosis of the Jaw in 2015 was 
of the opinion that ‘Stage 0’ may lead to overestimation of the disease’s prevalence. It argues that 
wrong diagnoses of osteonecrosis may be made in absence of clinical evidence of necrotic bone (3). 
However, the American Association of Oral and Maxillofacial Surgeons (AAOMS) has defended the 
use of ‘Stage 0’ as numerous studies have described up to 50% of stage 0 disease progressing to 
higher stages (2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Staging and treatment strategies for MRONJ (2) 
 
Prevention  
Several studies have found a lesser occurrence of osteonecrosis in patient groups where 
preventative measures were applied via a multidisciplinary unit. This would involve patients 
undergoing a comprehensive dental check-up before commencing antiresorptive therapy. Any 
source of acute infection or potential infection in the oral cavity would be identified and rectified to 
prevent exacerbation once the drug therapy has begun (2). Smaller studies have shown that good 
quality endodontic treatment with adequate coronal seal as opposed to extractions could reduce the 
risk of MRONJ (29,30). 
 
Cessation of therapy before oral surgery 
There is no consensus on a ‘drug holiday’ i.e. discontinuation of the drug for a definite period. It has 
been recommended that patients on antiresorptives for less than two years need not stop their 
medication, while patients on the drugs for more than four years would stop the medication until the 
surgical site healed. In 2011, the FDA stated that there was not enough evidence available to reach 
a consensus.  
Free bisphosphonate radicals are in circulation for a short time before excretion by the kidneys. The 
rest is bound to osteoclasts, which have a life span of two weeks. The serum level of 
bisphosphonates after two months would be very low, making this an adequate period before oral 
surgery (2). Some authors have suggested a three-month drug holiday for patients on denusomab 
(31). Since the terminal half-life of bisphosphonates is about 10 years, the usefulness of a drug 
holiday is questioned (32). The evidence base to support a drug holiday is weak and is mainly drawn 
from expert opinions. 
 
Patients with established osteonecrosis 
With established osteonecrosis, the aim of treatment is to keep patients free of pain and infection. 
There is also emphasis on maintaining the dentition to avoid requiring future dental surgery. In less 
advanced stages, conservative treatment is advised. In stages 3 or in cases where sequestrums are 
present, resection is favoured. Smoothening of rough necrotic areas will remove the source of 
irritation and allow optimal soft tissue healing (2). 
Opposing the AAOMS, Ristow supported surgical intervention in disease stages lower than ‘3’, 
quoting success rates of 85%. Conservative treatment is regarded by some as palliative treatment 
whereas surgical treatment is regarded as curative treatment. The main surgical approaches are 
debridement and resection. Debridement involves curettage to reduce necrotic bone. Resection is 
the removal of all the necrosis up to the margin of vital bone. Tension free mucoperiosteal coverage 
of the site offers the best healing chance. As necrotic bone does not revascularise, it should be 
thoroughly removed. Small remnants may cause recurrence or progression of the osteonecrosis. 
Also, irregular surfaces of the exposed bone are conducive to microbial colonisation; which is 
involved in the pathogenesis of osteonecrosis (31,33). 
 
Non-removal of exposed bone, it can be argued, will put patients at risk of future infection, especially 
in the case of immunocompromised patients. However, conservative treatment is useful in patients 
undergoing chemotherapy or whose medical statuses’ do not allow surgical intervention. Even 
though these measures are seen as temporary ones, 70% of patients remain pain free (31,34). 
 
Emerging treatments 
Growth factors like VEGF induce angiogenesis and osteoblastogenesis at injury site, promoting soft 
tissue healing. Growth factors, applied topically after resection, have achieved success in refractory 
osteonecrosis cases. Surgical lasers have been used for bony resections. Ozone therapy has 
increased haemoglobin concentration and number of red blood cells in avascular necrosis. 
Hyperbaric oxygen has several cellular benefits including wound healing through promotion of 
angiogenesis at wound peripheries, collagen formation and decrease of leukocyte adhesion (35). 
Mucosal healing following hyperbaric oxygen therapy has indeed been investigated. Although it 
showed improvement in the pain and quality of life scores, there was no statistical difference with the 
control group. Teriparatide, a powerful stimulant of both osteoclastic and osteoblastic activity is 
showing promising results. Reversal of inhibitory effects of bisphosphonates have been observed in 
vivo.  
Tocopherol and pentoxyfilline used in conjunction with tetracyclines have alleviated symptoms in 
patients and decreased areas of exposed bone (2,37,38). Pentoxyfilline increases oxygen delivery to 
tissues by increasing blood flow, decreasing blood viscosity and increasing cellular flexibility (36). 
Tocopherol improves endothelial function by its’ potent scavenging action on free oxygen radicals 
which impact necrosis (36). There is not yet enough evidence available to support any of these 
treatment modalities (2,37,38). 
 
 
Conclusion 
Antiresorptives and antiangiogenic drugs are indispensable in the treatment of malignant and 
skeletal conditions. As more data is collected on these novel drugs, pathophysiology will be better 
understood. From there, more robust clinical guidelines, backed up by solid evidence can be 
formulated. To reach that stage, it is imperative that dentists, maxillofacial surgeons and oncologists 
work as a team and communicate effectively.   
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